14-day Premium Trial Subscription Try For FreeTry Free

Range Low Price High Price Comment
30 days $23.53 $28.69 Friday, 3rd May 2024 INSM stock ended at $25.55. This is 0.429% less than the trading day before Thursday, 2nd May 2024. During the day the stock fluctuated 4.06% from a day low at $25.40 to a day high of $26.43.
90 days $23.53 $29.91
52 weeks $18.09 $32.00

Historical Insmed prices

Date Open High Low Close Volume
Feb 22, 2024 $27.60 $28.50 $25.06 $27.15 3 191 065
Feb 21, 2024 $29.07 $29.46 $28.10 $28.24 1 565 776
Feb 20, 2024 $29.12 $29.58 $28.84 $29.21 1 007 162
Feb 16, 2024 $28.64 $29.91 $28.27 $29.51 1 856 512
Feb 15, 2024 $27.76 $28.88 $27.60 $28.75 1 897 103
Feb 14, 2024 $26.80 $27.76 $26.66 $27.44 2 942 734
Feb 13, 2024 $27.02 $27.18 $26.33 $26.60 2 058 439
Feb 12, 2024 $28.09 $28.73 $27.52 $27.80 2 180 773
Feb 09, 2024 $28.67 $28.90 $28.12 $28.25 1 091 158
Feb 08, 2024 $28.94 $29.00 $28.18 $28.57 1 341 421
Feb 07, 2024 $28.89 $29.32 $28.59 $28.99 1 052 081
Feb 06, 2024 $28.18 $29.22 $27.99 $29.07 889 926
Feb 05, 2024 $27.84 $28.46 $27.61 $28.28 1 000 158
Feb 02, 2024 $28.16 $28.48 $27.59 $28.18 732 731
Feb 01, 2024 $28.02 $28.80 $28.00 $28.53 897 348
Jan 31, 2024 $28.89 $29.46 $27.74 $27.80 1 108 556
Jan 30, 2024 $28.10 $29.04 $27.84 $28.97 1 309 391
Jan 29, 2024 $27.67 $28.19 $27.25 $28.17 1 155 596
Jan 26, 2024 $27.97 $28.47 $27.56 $27.71 939 784
Jan 25, 2024 $27.61 $28.01 $27.33 $27.73 1 129 674
Jan 24, 2024 $28.40 $28.41 $27.31 $27.40 1 638 756
Jan 23, 2024 $28.54 $28.91 $27.99 $28.24 1 010 107
Jan 22, 2024 $28.28 $28.73 $28.11 $28.53 1 159 847
Jan 19, 2024 $28.60 $28.60 $27.81 $28.00 2 893 062
Jan 18, 2024 $28.84 $29.21 $28.03 $28.44 1 105 856
Click to get the best stock tips daily for free!

About Insmed

Insmed Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1 for the treatment of patients with bronchiectasis and other neutr... INSM Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT